Abstract:In the review we discuss the role of mineralocorticoid receptors (MRs) in regulation and pathological remodelling of the cardiovascular system and the therapeutic potential of pharmacological targeting of MRs in cardiovascular diseases. MRs are expressed in organs involved in cardiovascular homeostasis: brain, heart, kidneys and vessels. The excessive activation of MRs has deleterious effects on the cardiovascular system through sympatho-excitation, elevated salt appetite, and renal retention of salt with consequent positive sodium balance, fibrosis and remodelling of the heart and arteries, and with propensity for atrial and ventricular arrhythmias. Hence, it provides basis for a common pathophysiological milieu of hypertension and heart failure. Furthermore, MR-mediated changes in the cardiovascular system are potentiated by renin-angiotensin system and activation of angiotensin type 1 receptors. Due to low selectivity, MRs bind both aldosterone and GCs - cortisol in humans and corticosterone in laboratory rodents. The binding of GCs to MRs is determined by availability of tissue specific 11β-hydroxysteroid dehydrogenase of type 1 (11β-HSD1) or type 2 (11β-HSD2). 11β-HSD1 metabolizes GCs to either active or inactive metabolites depending on the presence of special cofactors, whereas 11β-HSD2 transforms GCs only into inactive metabolites allowing for selective stimulation of MRs by aldosterone. 11β-HSD2 is expressed in the vascular wall, renal epithelium and some groups of cardiovascular neurons in the brain. In contrast, cardiac expression of 11β-HSD2 is low, thus, both aldosterone and GCs interact with cardiac MRs. The importance of MRs in the cardiovascular pathology is reflected in clinical guidelines that recommend use of MR blockers, spironolactone and eplerenone, in the treatment of heart failure, myocardial infarction and hypertension. Furthermore, new MR blockers and selective inhibitors of 11β-HSD1 have been developed and are currently tested in clinical trials.

The the Multifaceted Functions of Mineralocorticoid Receptor in Cardiometabolic Disease

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.

Mineralocorticoid receptor antagonists and heart failure with preserved ejection fraction: current understanding and future prospects

Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals

Molecular pharmacology of mineralocorticoid receptor antagonists: The role of co-regulators

Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries

Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists

T-Cell Mineralocorticoid Receptor Controls Blood Pressure by Regulating Interferon-Gamma

The multifaceted role of the mineralocorticoid receptor in cancers

Coronary microvascular dysfunction and cardiovascular disease: Pathogenesis, associations and treatment strategies

Therapeutic applications of gut microbes in cardiometabolic diseases: current state and perspectives

Development of episodic and autobiographical memory: a cognitive neuroscience perspective.

Interplay between caveolin-1 and mineralocorticoid receptor in cardiometabolic disease

The mineralocorticoid system, cardiometabolic health and its interplay with adipose tissue

Mineralocorticoid Receptors in Vascular Smooth Muscle: Blood Pressure and Beyond

Transmission and prevalence of Burkholderia cepacia in Welsh cystic fibrosis patients.

Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction

Aldosterone's impact on kidney health: exploring the benefits of mineralocorticoid receptor antagonists for renal protection

The Mineralocorticoid Receptors in diabetic kidney disease

Role and mechanism of miRNA in cardiac microvascular endothelial cells in cardiovascular diseases

Ethacrynic acid in acute renal failure.